New Trends,Semaglutide is a once-weekly GLP-1–based medicine

The landscape surrounding semaglutide, a widely recognized GLP-1 medication, has seen significant developments, particularly concerning its availability and regulatory status. Recent FDA updates have clarified the situation regarding the previously ongoing semaglutide shortage, offering crucial information for both healthcare providers and patients.

Historically, the high demand for semaglutide injections, marketed under brand names like Ozempic and Wegovy, led to a significant shortage that persisted from early 2022 until late February 2025. However, a pivotal announcement on February 21, 2025, marked the official end of the semaglutide shortage. This declaration by the FDA signifies that the current supply of the drug can meet present and future demand, a welcome development for individuals relying on it for their health needs.

Beyond the resolution of the shortage, semaglutide continues to be a focal point for medical innovation and regulatory scrutiny. The drug is primarily known for its efficacy in managing type 2 diabetes, where it is used in conjunction with diet and exercise to improve glycemic control. Its role in weight management has also been solidified, with semaglutide received FDA approval under the brand name Wegovy for chronic weight management in adults with obesity or overweight with at least one weight-related condition. Clinical studies, such as the STEP 5 trial, have demonstrated substantial weight loss, with semaglutide 2.4 mg at week 104 in STEP 5 showing a mean weight loss of approximately 15%. Furthermore, research is exploring new frontiers, with oral semaglutide demonstrates potential to be the first oral GLP-1 RA therapy for children and adolescents with type 2 diabetes, indicating a broader application in the future.

The FDA has also been actively involved in ensuring the safety and integrity of semaglutide products. In a significant move, the FDA has seized dozens of units of counterfeit Ozempic (semaglutide) injection that were illegally distributed outside of Novo Nordisk's established channels. This action underscores the importance of obtaining these medications from legitimate sources to avoid potential health risks associated with unapproved or counterfeit products. The FDA has warned companies that have illegally sold unapproved drugs containing semaglutide, emphasizing the public health risks.

In parallel with the resolution of the shortage, there have been shifts in the availability of compounded versions of semaglutide. With the official shortage ending, compounded semaglutide is being phased out. While compounded GLP-1s are being phased out, some pharmacists do not believe they will disappear completely. However, the FDA's stance and regulatory actions, including a federal deadline ending the sale of off-brand weight-loss and diabetes medications, have significantly impacted access to these alternatives. A US judge's rejection of efforts by a compounded drugs industry group to continue producing alternative versions of Novo Nordisk's semaglutide further supports this trend. For those seeking weight management solutions, self-pay options are available for Wegovy and Zepbound.

In Canada, the expiration of patents for some semaglutide drugs is paving the way for more affordable generic options. This development highlights a global trend towards increased accessibility of semaglutide treatments.

It is crucial to remain informed about the latest developments regarding semaglutide, including potential semaglutide side effects and appropriate semaglutide dosing. While semaglutide has shown significant efficacy in improving glycemic control and reducing body weight, patients should always consult with their healthcare provider to discuss the best treatment options and ensure safe and effective use of the medication. The journey of semaglutide from a drug in shortage to a more accessible and evolving therapeutic agent reflects its growing importance in managing chronic conditions.